The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

August 17, 2023

Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.

August 16, 2023

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

August 16, 2023

The nation’s top-ranked UT MD Anderson Cancer Center and flagship UT Austin to build new hospitals as part of project.

August 15, 2023

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

August 15, 2023

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

August 15, 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

August 15, 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

August 10, 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

August 10, 2023

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

August 10, 2023

Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.

August 10, 2023

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

August 10, 2023

Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.

August 10, 2023

An overview of ongoing research in the endometrial cancer treatment space.

August 08, 2023

Krina K. Patel, MD, MSc, discusses the background of the phase 3 KarMMa-3 trial, which investigated idecabtagene vicleucel in patients with high-risk, relapsed/refractory multiple myeloma.

August 08, 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

August 08, 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

August 07, 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

August 03, 2023

The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, MD, an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search.

August 03, 2023

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.

August 03, 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.